Global Newswire by Notified: M&A

SEPTEMBER 27, 2023

27, 2023 (GLOBE NEWSWIRE) -- Mobiv Acquisition Corp (Nasdaq: MOBVU, MOBV, MOBVW) (the “Company”), a special purpose acquisition company, announces that it has filed its Definitive Proxy Statement in connection with the planned business combination with SRIVARU Holding Limited (“SRIVARU”), a commercial-stage provider of premium electric motorcycles.

Acquisitions 75

Acquisitions Business Initial Public Offering Underwriting 75

The New York Times: Mergers, Acquisitions and Dive

MARCH 7, 2025

The design tech company is exploring a public offering after regulators stymied its $20 billion sale to the software giant Adobe in 2023.

Sale 85

Sale Initial Public Offering IT Mergers and Acquisitions 85

Cooley M&A

JANUARY 30, 2024

As we look ahead to the 2024 proxy season (and beyond), let’s review the key 2023 trends and developments from activism playbooks, with a sharp focus on the ever-changing landscape in the technology and healthcare sectors. 4] Activists won 134 board seats globally in 2023, a 30% increase from 2022. Momentum building for 2024?

Private Equity 52

Private Equity M&A Capital Investors 52

Global Newswire by Notified: M&A

SEPTEMBER 19, 2023

19, 2023 (GLOBE NEWSWIRE) -- Btab Ecommerce Group, Inc. OTC: BBTT) (the “Company”), today announced it plans to expand its operations and revenues by acquiring more companies with the goal of forming a larger corporation prior to pursuing an initial public offering and uplisting to a national stock exchange such as NASDAQ.

Initial Public Offering 40

Initial Public Offering Business Corporation Stock 40

Global Newswire by Notified: M&A

JULY 3, 2023

Waxahachie, TX, July 03, 2023 (GLOBE NEWSWIRE) -- Minority Equality Opportunities Acquisition Inc.

Initial Public Offering 40

Initial Public Offering Shares IT Acquisitions 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. More than half of all life sciences M&A activity in 2023 was for private and small-cap biopharma sellers. billion, Mirati for $5.8 Let’s dig in.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

MergersCorp M&A International

OCTOBER 15, 2024

SPACs are publicly traded companies that raise capital through an initial public offering (IPO) with the primary aim of acquiring an existing private company, thereby enabling it to go public without undergoing the traditional IPO process.

Mergers and Acquisitions 52

Mergers and Acquisitions Advisory IPO Initial Public Offering 52

MergersCorp M&A International

JULY 5, 2024

In 2023 the primary market for global convertibles was more than double since 2022, with volumes reaching USD 78Bn via 115 new issues. The strained relations between the US and China, marked by broad financial sanctions and regulatory scrutiny have made initial public offering and follow on share sales nearly inaccessible for Chinese firms.

Debt 52

Debt Stock Initial Public Offering Capital 52

Focus Investment Banking

FEBRUARY 25, 2024

I still recall the metric that was drilled into me back then: hit $50 million in revenue and a few back-to-back years of profitability and you, too, can go public. The benefits of going public are significant. According to Wells Fargo, in 2023 there are five times as many private equity-backed firms in the U.S.

Private Equity 52

Private Equity IPO Equities Public Trading 52

Growth Business

JULY 11, 2023

3) Aquis Stock Exchange Aquis Stock Exchange , run by NEX, allows businesses to raise capital through Initial Public Offerings (IPOs). >See It had just ten companies at the beginning and had over 3,900 companies raising capital from investors as of April 2023. Though it can be very effective.

Finance 75

Finance Finance Business Debt 75

Cooley M&A

JANUARY 25, 2023

This post takes a deeper dive into what we see as the pivotal events and deals that propelled the life sciences industry in 2022, and our view on what to expect looking ahead to 2023. Let’s dig in. While parties may opt to test these new theories in court, companies should be ready for extended review periods and a skeptical FTC.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

APRIL 5, 2024

While the ruling has broad implications for many current arrangements (particularly stockholder agreements for public companies), it did provide a path forward, noting that many of these provisions would have been valid if included the corporation’s certificate of incorporation instead of the stockholder agreement.

M&A 52

M&A Mergers and Acquisitions Mergers Corporation 52

Cooley M&A

JANUARY 25, 2023

The numbers provide only a partial picture of the trends we saw in 2022 and where tech M&A activity is headed in 2023. Take-private transactions take center stage As we entered 2022, the ongoing correction in US public market valuations in the formerly high-flying tech sector seemed to auger a private equity tech take-private boom.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

NOVEMBER 18, 2024

These lofty valuations have been unattainable recently due to the aforementioned high interest rates, market saturation and increased competition, and other variables which created uncertainty and slowed dealmaking appetite in 2023 and 2024.

Private Equity 52

Private Equity Equities IPO Valuation 52

MergersCorp M&A International

MAY 27, 2025

After a boom in 2020 and 2021 that saw record-breaking volumes, the market cooled considerably in 2022 and 2023. The Basics At its core, a SPAC is a shell company with no commercial operations, formed solely to raise capital through an Initial Public Offering (IPO) with the express purpose of acquiring an existing private company.

IPO 52

IPO Mergers and Acquisitions Investors Negotiation 52

Cooley M&A

JANUARY 22, 2025

Fortunately, for those with the ever common resolution to slim down, the life sciences sector offers inspiration. Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and stuck with it throughout 2024. from 2023. [1]

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64